Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05617885 · ClinicalTrials.gov registry record · Phase 1
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
A Phase 1 study of Prostate Cancer and Metastatic Prostate Cancer, sponsored by Praful Ravi, MB BCHir, MRCP.
- Active
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT05617885 is a Phase 1 study of Prostate Cancer and Metastatic Prostate Cancer that is active but no longer recruiting, run by Praful Ravi, MB BCHir, MRCP. The registered enrollment target is 9 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05617885, a Phase 1 study of Prostate Cancer and Metastatic Prostate Cancer, is active but no longer recruiting, sponsored by Praful Ravi, MB BCHir, MRCP.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is trying to determine the safety and efficacy of the combination of two oral drugs, abemaciclib and darolutamide, with androgen deprivation therapy (ADT) in the treatment of metastatic, non-metastatic, and advanced prostate cancers. The first phase of the study is to establish a recommended dose for the second phase. The names of the study drugs and interventions involved in this study are: * Darolutamide * Abemaciclib * Androgen deprivation therapy (ADT) - this includes several different treatments, including Gonadotropin-Releasing Hormone (GnRH) antagonists and agonists It is expected that about 93 people will take part in the research study. Treatment is expected to last 6 months with a follow up period of up to 4.5 years.
Conditions Studied
Interventions
- DRUG Darolutamide
- DRUG Abemaciclib
- DRUG Degarelix
- DRUG GNRH-A Leuprolide Acetate
- DRUG GNRH-A Goserelin
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2023-08-09 |
| Est. Completion | 2026-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05617885
The ClinicalTrials.gov registry entry for NCT05617885 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Praful Ravi, MB BCHir, MRCP, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 5 interventions - of which Darolutamide is the first listed.
NCT05617885 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05617885 about?
NCT05617885 is a clinical study titled "Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer". This research study is trying to determine the safety and efficacy of the combination of two oral drugs, abemaciclib and darolutamide, with androgen deprivation therapy (ADT) in the treatment of metastatic, non-metastatic, and advanced prostate cancers. The first phase of the study is to establish a...
What is the current status of trial NCT05617885?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2023-08-09. Estimated completion is 2026-06-01.
What conditions does trial NCT05617885 study?
This clinical trial studies the following conditions: Prostate Cancer, Metastatic Prostate Cancer, Non-metastatic Prostate Cancer.
What interventions are being tested in trial NCT05617885?
The interventions under investigation include: Darolutamide (DRUG), Abemaciclib (DRUG), Degarelix (DRUG), GNRH-A Leuprolide Acetate (DRUG), GNRH-A Goserelin (DRUG).
Who is sponsoring clinical trial NCT05617885?
This trial is sponsored by Praful Ravi, MB BCHir, MRCP, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05617885 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RECRUITING · Phase 1
-
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
RECRUITING · Phase 1
-
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.